What Is LL-37?

1. How does LL-37 work?

Your body first makes a larger precursor protein, hCAP18. Enzymes then release LL-37 from it. Sørensen and colleagues demonstrated this processing by proteinase 3 after neutrophils, a type of white blood cell, released their contents. Producing the precursor and releasing the active peptide are separate biological steps.

LL-37 has a positive electrical charge and regions that interact with membranes. It can act directly against susceptible microbes, while also changing how microbes organize and how human cells respond. Experimental conditions affect the result: the Overhage biofilm paper notes that physiological salt concentrations can weaken its direct antimicrobial activity.

Repair involves another mechanism. In Tokumaru and colleagues’ 2005 cell study, LL-37 stimulated migration of keratinocytes, the cells that form the skin’s outer layer. Blocking epidermal growth factor receptor signaling blocked this effect. Cells moving into a damaged area provide a rationale for wound research; the experiment itself did not measure healing in patients.

The general peptide guide explains how sequence and delivery influence a peptide’s behavior. For LL-37, local exposure is especially relevant because the human wound studies put a defined preparation directly onto the tissue being treated.

2. LL-37 benefits: what do the human trials show?

Two randomized venous-leg-ulcer studies give a more useful answer than a list of proposed benefits. These wounds involve impaired venous circulation, and their treatment context differs from a gym injury or recurrent infection.

The 2014 study tested concentrations of 0.5, 1.6 and 3.2 mg/mL. At 0.5 mg/mL, the healing-rate constant was about six times the placebo value, with p = 0.003. That describes a mathematical measure of wound shrinkage. It does not mean every wound closed six times faster. The highest concentration showed no healing advantage, so even this encouraging experiment did not support a simple “more works better” dose response.

The larger study gives absolute numbers. The HEAL LL-37 results and published paper reported estimated confirmed complete closure in 26.5% of the lower-concentration group, 24.7% of the higher-concentration group and 25.3% of the placebo group. None of the overall healing comparisons was statistically significant.

A post hoc analysis suggested benefit in wounds measuring at least 10 cm². Post hoc means researchers examined the subgroup after the main analysis; it generates a hypothesis for another trial. It does not turn the overall result into a positive one.

These trials studied chronic ulcers treated locally. They supply no recovery estimate for injected LL-37, tendon damage or muscle soreness.

3. LL-37 and biofilms

A biofilm is a community of microbes attached to a surface within material they produce. That organization can make an infection harder to treat.

In Overhage and colleagues’ 2008 experiment, LL-37 inhibited Pseudomonas aeruginosa biofilm formation at 0.5 micrograms/mL, below the concentration needed to inhibit bacterial growth in that assay. Researchers observed reduced attachment, altered bacterial movement and changes in signaling associated with biofilm development. They also found effects on existing biofilms.

The experiment supports further investigation of LL-37 as an antibiofilm agent. It does not establish that a subcutaneous injection reaches a sinus, gut or implanted-device biofilm at an effective concentration. Nor does altering a biofilm measurement establish that an infection has cleared.

A clinical claim needs a named organism, a defined infection site, a tested formulation and patient outcomes. “Biofilm breaker” leaves all four unspecified.

4. Does LL-37 treat Lyme disease or chronic infections?

A result against Pseudomonas cannot establish activity against Borrelia, the bacteria responsible for Lyme disease. Antimicrobial effects vary by organism and experimental conditions.

Marchal and colleagues’ 2011 study examined how tick saliva affects skin-cell defenses during Lyme transmission. The antimicrobial peptides tested, including LL-37, did not kill Borrelia under the study conditions, although the researchers observed transient effects on bacterial motility. This was a laboratory experiment, not a treatment trial.

The controlled human evidence reviewed here does not establish LL-37 as a treatment for Lyme disease or persistent symptoms attributed to infection. Wound closure, bacterial movement and patient recovery are different outcomes.

Feeling worse after an experimental product also does not prove that microbes are dying. A symptom change alone cannot distinguish an adverse reaction from progression of illness or another cause. Persistent symptoms need assessment rather than an automatic “die-off” explanation.

5. Immune effects, inflammation and psoriasis

“Immune boosting” is too vague to describe LL-37’s biology. An immune response needs to recognize a threat, act in the right place and stop when the threat has passed.

Lande and colleagues’ 2007 psoriasis study showed that LL-37 binds DNA released from the body’s own cells. These complexes allow certain immune cells to recognize that DNA through a receptor called TLR9 and produce interferon, an immune-signaling protein. DNA that would otherwise provoke little response becomes an inflammatory trigger.

This mechanism helps explain LL-37’s involvement in psoriasis. It does not quantify the chance that an injection will cause a flare or autoimmune disease. It does show why naturally occurring LL-37 cannot be assumed safe at any added exposure.

For someone tracking inflammation, a higher LL-37 measurement cannot automatically be treated as progress. It may reflect an active response to injury or disease. A biomarker needs interpretation in the context of symptoms, diagnosis and the tissue being measured.

6. Vitamin D and LL-37

Wang and colleagues’ 2004 experiments showed that active vitamin D can induce expression of the human cathelicidin gene. The researchers identified vitamin D response elements in the gene’s regulatory region, providing a molecular explanation for the connection.

That finding concerns gene regulation. It does not establish a vitamin D supplement dose that produces a particular LL-37 concentration at an infection site. Increasing precursor production, releasing active peptide and improving a clinical outcome each require additional evidence.

Vitamin D supplementation and synthetic LL-37 administration create different exposures. The gene-expression experiment cannot validate high-dose supplementation as an infection treatment or a substitute for an LL-37 drug trial.

7. LL-37 dosage, injections and half-life

The topical concentrations above describe research formulations applied to wounds. They are not injection instructions. A concentration in mg/mL says how much peptide a liquid contains; it does not establish the amount delivered to another tissue after injection.

No clinically validated subcutaneous dose, cycle length or maintenance schedule for immune enhancement emerges from these trials. Likewise, they do not establish a dependable human subcutaneous half-life. A precise half-life claim needs a pharmacokinetic study identifying the preparation, route and measurement method.

Bioavailability describes how much of an administered substance reaches circulation, but researchers also need to know whether active LL-37 reaches the intended tissue. Neither can be inferred from the amount printed on a vial.

A peptide half-life model calculates what follows from its input. Entering an unsupported half-life gives a curve without establishing the underlying exposure.

8. LL-37 side effects and FDA status

The wound trials reported acceptable tolerability for their topical preparations. They cannot establish side-effect frequencies for repeated injections or long-term systemic exposure.

The FDA’s LL-37 safety entry flags potential immunogenicity for certain routes, peptide-related impurities and difficulty characterizing the active ingredient. Immunogenicity means a substance can provoke an immune response. FDA also reports insufficient safety information to determine potential harm.

LL-37 has no FDA-approved medical use as of September 21, 2026. A research label or a compounding service does not establish that a product has passed an approval review for safety and effectiveness.

Separate product quality from biological safety when reading a supplier’s claims. A purity percentage alone cannot establish sterility, the amount of peptide delivered or the consequences of repeated exposure. Even a correctly identified peptide still needs human safety data for its intended use.

9. LL-37 vs BPC-157, KPV and peptide stacks

These compounds attract overlapping interest, but their research asks different questions. BPC-157 is investigated largely for repair effects, KPV for anti-inflammatory activity, and TB-500 for recovery claims complicated by its distinction from full-length thymosin beta-4.

LL-37 adds antimicrobial and immune-signaling questions. The papers reviewed here do not establish that combining it with those peptides improves recovery, gut symptoms or infection outcomes. Effects from separate experiments cannot be added together to predict a stack’s benefit.

For a personal symptom record, log diagnoses, medications, training changes and the timing of new exposures. If several compounds start together, improvement or deterioration cannot reliably be assigned to LL-37. A useful future trial would test a defined preparation against a comparison group and measure the outcome you care about: confirmed infection clearance, wound closure or functional recovery, with adverse-event follow-up.

10. LL-37 FAQ

• What is LL-37 peptide used for?

  Researchers study LL-37 for antimicrobial activity, immune signaling and wound repair. Human trials have tested topical preparations for venous leg ulcers. Immune enhancement and chronic-infection claims for injections remain unproven.

• What does LL-37 stand for?

  The two Ls refer to leucine, the first two amino acids in the sequence. The number 37 is the peptide's total amino-acid count. It is released from the larger human cathelicidin precursor hCAP18.

• Does LL-37 break down biofilms?

  A 2008 laboratory study found reduced Pseudomonas aeruginosa biofilm formation and effects on existing biofilms. It did not establish clearance of biofilm infections in patients.

• Does LL-37 treat Lyme disease?

  Controlled human evidence reviewed here does not establish LL-37 as a Lyme treatment. A laboratory study of tick saliva and Borrelia found that the tested antimicrobial peptides did not kill the bacteria under its experimental conditions.

• What is the recommended LL-37 dosage?

  There is no clinically validated injection dose or cycle for immune enhancement. Topical wound-study concentrations cannot be converted into a subcutaneous protocol.

• What are the side effects of LL-37?

  Human injection side-effect rates are not established. Topical wound trials reported acceptable tolerability for their preparations, while FDA identifies possible immunogenicity and peptide-quality concerns.

• Does vitamin D increase LL-37?

  Active vitamin D can increase expression of the human cathelicidin gene in laboratory experiments. This does not establish that high-dose supplements reproduce LL-37 treatment or improve infection outcomes through that pathway.

• Is LL-37 FDA-approved?

  LL-37 has no FDA-approved medical use as of September 21, 2026. Availability from a compounder or research supplier does not establish approval.

11. Sources